Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs

被引:0
|
作者
Li, Qingsong [1 ,2 ,3 ]
Liang, Na [1 ,2 ,3 ]
Ouyang, Weiwei [1 ,2 ,3 ]
Su, Shengfa [1 ,2 ,3 ]
Ma, Zhu [1 ,2 ]
Geng, Yichao [1 ,2 ,3 ]
Hu, Yinxiang [1 ,2 ,3 ]
Li, Huiqin [1 ,2 ]
Lu, Bing [1 ,2 ,3 ]
机构
[1] Guizhou Med Univ, Affiliated Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[2] Guizhou Med Univ, Affiliated Canc Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[3] Guizhou Med Univ, Clin Med Coll, Teaching & Res Dept Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
关键词
Time; Non-small cell lung cancer (NSCLC); EGFR-TKIs; Primary tumor radiotherapy; Overall survival; TYROSINE KINASE INHIBITORS; OPEN-LABEL; PHASE-III; ADENOCARCINOMA HISTOLOGY; CONCURRENT CHEMOTHERAPY; MAINTENANCE THERAPY; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; RADIATION-THERAPY; GEFITINIB;
D O I
10.1186/s12885-024-12826-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long-term overall survival(OS)and provide a theoretical basis for further clinical research. Patients and methods In total, 238 patients with EGFR-TKIs and OS >= 12 months were statistically analysed. Patients were grouped: the D group without primary tumor radiotherapy and the R group with it. The R group were divided into three groups according to the interval between the start of EGFR-TKIs and the start of primary tumor radiotherapy: R0 - 30(<30 days), R30 - PD(>= 30 days and disease stable), and R-PD(radiotherapy after disease progression). The Kaplan-Meier method and log-rank test were used for survival analyses. Exploratory landmark analyses were investigated. Results The OS rates at 1, 2, 3, 5 years for the R group and D group were 96.8%, 62.9%, 38.3%, 17.1%, and 95.6%, 37.7%, 21.8%, 2.9%, respectively; the corresponding MST was 29 months(95% CI: 24.3-33.7) for the R group and 22 months(95% CI: 20.4-23.6) for the D group (chi(2) = 13.480, p<0.001). Multivariate analysis revealed that primary tumor radiotherapy was independent predictors of prolonged OS. Among the four groups, The R30 - PD appeared to have the best OS (D, chi(2) = 19.307, p<0.001;R0 - 30, chi(2) = 11.687, p = 0.01; R-PD, chi(2) = 4.086, p = 0.043). Landmark analyses(22 months) showed the R30 - PD group had a significant long-term OS. The incidence of radiation pneumonitis >= grade 2 was17.3%(n = 19)and radiation esophagitis >= grade 2 was observed in 32 patients(29.1%). Conclusions Our results showed that primary tumour radiotherapy may prolong long-term OS with acceptable toxicities. Appropriate delay(R30 - PD)of primary tumour radiotherapy may be the best choice. Premature radiotherapy(R0 - 30) and radiotherapy after disease progression (R-PD)may not be reasonable for long-term OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
    Qi, Yuexiao
    Xia, Xiaojun
    Shao, Lihua
    Guo, Liyun
    Dong, Yumei
    Tian, Jinhui
    Xu, Lijun
    Niu, Ruijun
    Wei, Shihong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Subsequent Treatment Choices for Patients with Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer: Restore after a Drug Holiday or Switch to another EGFR-TKI?
    Song, Tao
    Yu, Wei
    Wu, Shi-Xiu
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (01) : 205 - 213
  • [43] First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Shuyun Wang
    Aiqin Gao
    Jie Liu
    Yuping Sun
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 443 - 453
  • [44] Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
    Mountzios, Giannis
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [45] Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases
    Yu, Xiaoqing
    Sheng, Jiamin
    Pan, Guoqiang
    Fan, Yun
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (05) : 1121 - 1128
  • [46] Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis
    Jiang, Tao
    Min, Weijie
    Li, Yanan
    Yue, Zhijian
    Wu, Chunyan
    Zhou, Caicun
    CANCER MEDICINE, 2016, 5 (06): : 1055 - 1065
  • [47] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
    Zhixin Sheng
    Yanxia Zhang
    Medical Oncology, 2015, 32
  • [48] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
    Wang, Shuhang
    Su, Xiaomei
    Bai, Hua
    Zhao, Jun
    Duan, Jianchun
    An, Tongtong
    Zhuo, Minglei
    Wang, Zhijie
    Wu, Meina
    Li, Zhenxiang
    Zhu, Jian
    Wang, Jie
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [49] Epidemiology, diagnostics and long-term overall survival of patients with non-small cell lung cancer in the Brest Region
    Panko, Siarhei
    Karpitski, Aleksandr
    Shelepen, Konstantin
    Kazarez, Mikalaj
    Vakulich, Denis
    Boufalik, Rostislaw
    Shestiuk, Andrej
    Zhurbenka, Genadz
    Ignatiuk, Alaksandr
    MEDICAL STUDIES-STUDIA MEDYCZNE, 2013, 29 (03) : 203 - 212
  • [50] Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer
    Keflee, Rashidi Dzul
    Leong, Kok Hoong
    Ogawa, Satoshi
    Bignon, Jerome
    Chan, Mun Chiang
    Kong, Kin Weng
    BIOCHEMICAL PHARMACOLOGY, 2022, 205